Browsing Tag
Genentech
36 posts
Genentech’s Columvi combo fails to secure FDA approval for second-line DLBCL use
FDA rejects Genentech’s sBLA for Columvi-GemOx in second-line DLBCL treatment; survival benefit data deemed insufficient for U.S. approval.
Genentech faces FDA setback for Columvi GemOx in second-line diffuse large B-cell lymphoma as SKYGLO trial becomes key to future U.S. expansion
Genentech’s Columvi GemOx sBLA faces FDA rejection in second-line DLBCL. Analysts await SKYGLO trial data for U.S. approval prospects. Learn more.
Genentech’s Lunsumio and Polivy combination triples remission in relapsed large B-cell lymphoma
Genentech's chemo-free Lunsumio and Polivy combo tripled remission time in relapsed B-cell lymphoma, signaling a shift toward outpatient oncology treatment.
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market.
Atezolizumab slashes colon cancer recurrence by 50% in ATOMIC trial: ASCO 2025 breakthrough
Genentech’s Tecentriq cuts recurrence risk by 50% in dMMR colon cancer, setting the stage for new adjuvant approvals after ATOMIC trial success.
ATOMIC trial breakthrough: Atezolizumab + FOLFOX cuts colon cancer recurrence risk by 50%
Atezolizumab plus FOLFOX slashes recurrence risk in stage III dMMR colon cancer, says ATOMIC trial at ASCO 2025. Is this the new standard of care?
Roche bets big on America: $50bn to fuel next-gen weight loss drugs and diagnostics boom
Discover how Roche’s $50 billion U.S. investment is transforming pharma R&D, diagnostics, and job creation across eight states and reshaping global exports.
Recursion Pharmaceuticals’ stock plunges 7% after shock Q4 loss – What went wrong?
Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, reported a significantly wider loss for…
FDA approves Genentech’s Evrysdi tablet as first SMA treatment in tablet form
In a significant development for the treatment of spinal muscular atrophy (SMA), the U.S. Food and Drug Administration…
Roche’s Gazyva shows superior efficacy in lupus nephritis treatment, Phase III trial data reveals
Roche has announced promising new data from its phase III REGENCY clinical trial, published in the New England…